Covalent Drug Discovery Summit
By
Hanson Wade
2 Followers
Follow
Event Details
Covalent Drug Discovery Summit
The field of targeted covalent therapeutics is seeing a surge of activity, with both new and established companies investing heavily in the space. The inaugural Covalent Drug Discovery Summit has been built alongside industry experts to provide a dedicated forum to tackle associated challenges and advance covalent therapeutics; previously only afforded a small feature in larger 'small molecule' conferences.
As the very first meeting solely focused on covalent therapeutics, the 18+ speaker faculty boasts leaders from large pharma, new biotech and academia. This is the summit to meet 80+ covalency experts gathering to solve target selectivity, hit screening, lead optimization, and covalent warhead design to carve out covalency's niche for targeting the "undruggable" proteome.
URLs:
Brochure: https://go.evvnt.com/1900494-0?pid=10018
Tickets: https://go.evvnt.com/1900494-2?pid=10018
Website: https://go.evvnt.com/1900494-3?pid=10018
Prices:
Drug Developer Pricing - Conference Only: USD 2999.00,
Drug Developer Pricing - Conference + 1 Workshop: USD 3648.00,
Drug Developer Pricing - Conference + 2 Workshops: USD 4297.00,
Academic Pricing - Conference Only: USD 2599.00,
Academic Pricing - Conference + 1 Workshop: USD 3148.00,
Academic Pricing - Conference + 2 Workshops: USD 3697.00,
Solution Provider Pricing - Conference Only: USD 3799.00,
Solution Provider Pricing - Conference + 1 Workshop: USD 4548.00,
Solution Provider Pricing - Conference + 2 Workshops: USD 5297.00
Speakers: David Weinstein, Vice President and Head of Chemistry, Vividion Therapeutics, Eranthie Weerapana, Professor of Chemistry, Boston College, Herman Lik Hang Yuen, Associate Director, DEL Informatics and Cheminformatics, Nurix, Ivan Cornella, Chief Scientific Officer, Covant Therapeutics, Jeff McKenna, Director of Hit Generation and Covalent Drug Discovery, Novartis AG, Jeffrey Martin, Principal Scientist, Biogen, John Knox, Vice President - Structural Chemistry and Discovery Sciences, Revolution Medicines Inc., Laura D’Agostino, Vice President of Chemistry, Dunad Therapeutics, Lei Wang, Professor, University of Califorina, San Francisco, Neil Dhawan, Chief Executive Officer, Totus Medicines, Ping Cao, Chief Executive Officer, Bridgene Biosciences, Ruben Tommasi, Chief Scientific Officer, Dunad Therapeutics, Simona Cotesta, Director of Global Discovery Chemistry, Novartis, Stephen Baker, Head Of Chemistry Reactive, Biosciences, Thorsten Kirschberg, Executive Vice President of Chemistry, Biomea Fusion, Tinghu Zhang, Senior Scientist, (Nathanael Gray’s Lab) Stanford University, Ziyang Zhang, Professor of Chemistry and Chemical Biology, University of California Berkeley
As the very first meeting solely focused on covalent therapeutics, the 18+ speaker faculty boasts leaders from large pharma, new biotech and academia. This is the summit to meet 80+ covalency experts gathering to solve target selectivity, hit screening, lead optimization, and covalent warhead design to carve out covalency's niche for targeting the "undruggable" proteome.
URLs:
Brochure: https://go.evvnt.com/1900494-0?pid=10018
Tickets: https://go.evvnt.com/1900494-2?pid=10018
Website: https://go.evvnt.com/1900494-3?pid=10018
Prices:
Drug Developer Pricing - Conference Only: USD 2999.00,
Drug Developer Pricing - Conference + 1 Workshop: USD 3648.00,
Drug Developer Pricing - Conference + 2 Workshops: USD 4297.00,
Academic Pricing - Conference Only: USD 2599.00,
Academic Pricing - Conference + 1 Workshop: USD 3148.00,
Academic Pricing - Conference + 2 Workshops: USD 3697.00,
Solution Provider Pricing - Conference Only: USD 3799.00,
Solution Provider Pricing - Conference + 1 Workshop: USD 4548.00,
Solution Provider Pricing - Conference + 2 Workshops: USD 5297.00
Speakers: David Weinstein, Vice President and Head of Chemistry, Vividion Therapeutics, Eranthie Weerapana, Professor of Chemistry, Boston College, Herman Lik Hang Yuen, Associate Director, DEL Informatics and Cheminformatics, Nurix, Ivan Cornella, Chief Scientific Officer, Covant Therapeutics, Jeff McKenna, Director of Hit Generation and Covalent Drug Discovery, Novartis AG, Jeffrey Martin, Principal Scientist, Biogen, John Knox, Vice President - Structural Chemistry and Discovery Sciences, Revolution Medicines Inc., Laura D’Agostino, Vice President of Chemistry, Dunad Therapeutics, Lei Wang, Professor, University of Califorina, San Francisco, Neil Dhawan, Chief Executive Officer, Totus Medicines, Ping Cao, Chief Executive Officer, Bridgene Biosciences, Ruben Tommasi, Chief Scientific Officer, Dunad Therapeutics, Simona Cotesta, Director of Global Discovery Chemistry, Novartis, Stephen Baker, Head Of Chemistry Reactive, Biosciences, Thorsten Kirschberg, Executive Vice President of Chemistry, Biomea Fusion, Tinghu Zhang, Senior Scientist, (Nathanael Gray’s Lab) Stanford University, Ziyang Zhang, Professor of Chemistry and Chemical Biology, University of California Berkeley
Entry Fees
Free Registration
Categories
Event Frequency
One Time
Event Timings
(GMT-5:00) Central Time (US and Canada)
07:30 AM - 05:00 PM (Dec 12, Dec 13, Dec 14) (Public)
Speakers
Organizer
Hanson Wade
2 Followers
Follow
Hanson Wade specialises in bringing people together through outstanding business conferences and year round community contact.
More Events By Hanson Wade
Comments on Covalent Drug Discovery Summit
You must Login to write a comment.
Peoples Interested in Visit
0 Peoples Interested to Visit
Event Location
Hilton Boston Back Bay
40, Dalton Street, Back Bay, Boston ,
Boston 02115, Massachusetts, United States
Boston 02115, Massachusetts, United States
Official Link :